The Journal of dermatological treatmentHumansMalePsoriasisFemaleQuality of Life
Reduction of impairment of sexual activity in patients with genital psoriasis treated with risankizumab: interim results of a real-world study.
Nesrine Ben-Anaya, Tony Yip, Christina Sorbe, Thomas Bickert, Johannes Hockmann, Carl-Philipp Bürkle, Kristina Lohmann, Marius Schild, Matthias Augustin, Ralph von Kiedrowski
Published: 202510.1080/09546634.2025.2585248
Abstract
Psoriasis involving the genital region (GenPsO) is associated with impaired quality of life (QoL), including sexual burden and avoidance of sexual intercourse. There is limited data on the effectiveness of risankizumab in GenPsO on patients' QoL and…
Preview only. Read the full abstract at the source